Beyond the Brand: Preparing for the Next Phase of Competition and Accessibility in the Apixaban Segment
The strength of the therapeutic area dedicated to apixaban lies in its capacity to address a spectrum of thromboembolic disorders, dividing the market into distinct yet interconnected segments. The primary and arguably most critical segment is the prevention of stroke and systemic embolism in patients suffering from non-valvular atrial fibrillation. The sheer number of individuals affected...
0 Comments 0 Shares 146 Views 0 Reviews